Ibrutinib and Rituximab Show Promise in Relapsed/Refractory Mantle Cell Lymphoma
A phase II trial is investigating the efficacy of ibrutinib and rituximab in treating relapsed or refractory mantle cell lymphoma.
Asset / Drug
Drug and asset intelligence for Ibrutinib with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.